Research & Evidence
Floater-focused research. Broader daily eye nutrition.
Explore research on eye floaters, retinal carotenoids, macular pigment, and tear-film measures related to dry eye and screen use. See the evidence ↓Our approach
Built around floater research.
Broadened for daily eye nutrition.
Haro Clear combines five nutrient categories represented in
FLIES
Floater Intervention Study (FLIES): a 2021 trial of a five-nutrient supplement for adults with symptomatic vitreous floaters.
, 900 mg of fruit enzymes per daily serving, and the retinal carotenoids lutein and zeaxanthin.
Retinal carotenoids
8mglutein + zeaxanthin
Carotenoids found in the retina and lens, included in every daily Haro Clear serving.
Daily enzyme serving
900mgbromelain + papain
The largest ingredients in the formula by weight.
FLIES Floater Intervention Study (FLIES): a 2021 trial of a five-nutrient supplement for adults with symptomatic vitreous floaters. connection
Five targeted micronutrients.
Broader eye nutrition
9complementary ingredients
Enzymes, carotenoids and targeted micronutrients in one routine.Lutein and zeaxanthin research: macular pigment and screen-use studies
Lutein and zeaxanthin are carotenoids found in the retina and lens. In the macula, the central area used for detailed vision, they contribute to macular pigment—a natural filter that absorbs blue light. Researchers study how these nutrients relate to visual performance and eye comfort.
What was tested?
2025 screen-use trial: Adults using screens at least six hours daily received 10 mg lutein plus 2 mg zeaxanthin isomers or placebo each day. The trial was randomized and double-blind.
2014 visual-performance trial: A randomized, double-blind trial enrolled 115 young, healthy adults. Participants received 10 mg lutein plus 2 mg zeaxanthin daily or placebo for one year.
What did researchers find?
2025 screen-use trial: Compared with placebo, the supplement group improved on tear-production, tear-film stability and bright-light recovery tests. Self-reported symptoms and contrast sensitivity showed no significant between-group improvement.
2014 visual-performance trial: Macular pigment density, recovery after bright light and a color-contrast test improved versus placebo. The glare-disability test did not show a significant treatment benefit.
How to read the findings
Measured improvements and everyday symptom relief are different outcomes. Results relate to the formula, dose and population studied; Haro Clear uses a different nine-ingredient formula with a two-capsule daily serving. Screen-use outcomes measured in this trial included tear-film function and visual recovery; protection from retinal damage was not assessed.
Funding and disclosures
The 2025 trial was funded by Bio-gen Extracts Pvt. Ltd., which supplied the study capsules. The 2014 trial was supported by DSM Nutritional Products Ltd. and Kemin Foods L.C. Both papers disclose commercial relationships.
How is macular pigment measured?
Macular pigment optical density measures how strongly that pigment absorbs light. It is distinct from a person’s symptom score.
- Read the 2025 screen-use studyLopresti & Smith (2025) · Frontiers in Nutrition · 12:1522302 · DOI: 10.3389/fnut.2025.1522302
- Read the 2014 macular pigment studyHammond et al. (2014) · Investigative Ophthalmology & Visual Science · 55(12):8583–8589 · DOI: 10.1167/iovs.14-15573
About our processResearch transparency
We cite the sources behind our study explanations and identify the tested ingredients, doses, populations and findings. Results apply to the formulas and people studied; they do not establish equivalent results for Haro Clear.
Disclosure: Haro Health owns and sells Haro Clear.
We review affected content when the label, source information or evidence changes. To flag an error, email hello@harohealth.com with the page link and the wording you want us to check. Please do not send private medical records.
Review status: Updated study explanations are under review. Previously recorded review: September 13, 2026.
Ready for your daily routine?